HIV Type 1 Viral Encephalitis After Development of Viral Resistance to Plasma Suppressive Antiretroviral Therapy
- 1 January 2012
- journal article
- case report
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 28 (1) , 83-86
Abstract
HIV-1 viral encephalitis produced by antiretroviral-resistant strains in cerebrospinal fluid (CSF), despite suppression of plasma HIV-1 RNA, has been rarely described. We report two cases of symptomatic viral encephalitis demonstrated by clinical, magnetic resonance imaging (MRI), and an inflammatory CSF profile. Viral load in CSF was 24,000 and 6850 copies/ml, whereas plasma HIV RNA level was undetectable since the beginning of therapy. A resistance test in CSF showed genotypic mutations confering resistance to the drugs the patients received for more than 2 years. In the two cases, a high baseline HIV RNA level, a low nadir CD4(+) count, and suboptimal CSF levels of atazanavir were considered as the risk factors for developing encephalitis. The two cases did not resolve with a change to antiretroviral drugs with better CNS penetration, but they had complete clinical and MRI recovery after changing to therapy considering both CNS viral resistance and penetration.Keywords
This publication has 19 references indexed in Scilit:
- Could differential virological characteristics account for ongoing viral replication and insidious damage of the brain during HIV 1 infection of the central nervous system?Journal of Clinical Virology, 2010
- Detectable cerebrospinal fluid HIV RNA with associated neurological deficits, despite suppression of HIV replication in the plasma compartmentAIDS, 2009
- HIV-1 Meningoencephalitis in Patients on Effective HAARTHIV Research & Clinical Practice, 2009
- Compartmentalized Human Immunodeficiency Virus Type 1 Originates from Long-Lived Cells in Some Subjects with HIV-1–Associated DementiaPLOS Pathogens, 2009
- Low atazanavir concentrations in cerebrospinal fluidAIDS, 2009
- Validation of the CNS Penetration-Effectiveness Rank for Quantifying Antiretroviral Penetration Into the Central Nervous SystemArchives of Neurology, 2008
- Treatment Benefit on Cerebrospinal Fluid HIV‐1 Levels in the Setting of Systemic Virological Suppression and FailureThe Journal of Infectious Diseases, 2006
- Independent Evolution of Human Immunodeficiency Virus (HIV) Drug Resistance Mutations in Diverse Areas of the Brain in HIV-Infected Patients, with and without Dementia, on Antiretroviral TreatmentJournal of Virology, 2004
- Discordant Human Immunodeficiency Virus Type 1 Drug Resistance Mutations, Including K103N, Observed in Cerebrospinal Fluid and PlasmaClinical Infectious Diseases, 2002
- Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: Clinical correlationsHIV Research & Clinical Practice, 2002